…
Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. The company was founded in 1994 and is based in Lexington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Antigenics Inc is a publicly traded Pink Sheets company with limited recent disclosures that appears to have been involved in biotechnology activities; current operations and any product pipeline are not clearly documented. Long-term growth would depend on successful clinical development or licensing and the company's ability to raise capital, so investors may view it as a speculative play if transparency and execution improve.
Key risks are scant public information, very low liquidity, likely operating losses and financing needs, regulatory and clinical uncertainty if assets exist, and material delisting or corporate restructuring risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 |
Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. The company was founded in 1994 and is based in Lexington, Massachusetts.
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.